Outcomes based Contracts between Pharma and Payers Preparing for the Future, Now!
Outcomes/risk-based contracts between pharma and payers have been talked about for years. Europe has taken more of an aggressive approach to making it happen. The US has taken more of a cautious approach. But times are changing, and pharma needs to prepare for the future, now!
Key Takeaways include
o What is outcomes-, risk-, or value-based contracting?
o What is driving this?
o How does it benefit pharma, payers, patients?
o What metrics are critical to develop then monitor these contracts?
o How can pharma prove the safety, efficacy, and cost effectiveness of its products, demonstrating the impact and outcomes needed to meet contractual obligations?